All News
ICYMI: Shifting Trends in Initial RA Treatment Approaches
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
Read Article
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
When should you consider off-label use of JAKi?
Read Article
Novel TYK2 inhibitor Zasocitinib
Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and hematopoietic axes. Therefore, it is hypothesized that TYK2-targeted agents could be effective in rheumatic disease, with a potential for less off-target adverse effects. Zasocitinib is a new, oral TYK2 inhibitor generated using artificial intelligence-assisted compound design.
Read Article
RA-ILD in the Spotlight at ACR 2024
Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options. There is also a shocking lack of trial data. This year, there were two oral sessions dedicated to RA-ILD, one of which even the overflow room was standing room only, in addition to many posters.
Read Article
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
Read Article
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
Playing it Safe with RA? JAK vs. TNF Debate
Reported safety signals, at odds with the efficacy of these medications, have left rheumatology clinicians in a difficult position when considering when during a patient’s treatment course and in which patients, specifically, JAKi should be used. Two abstracts from ACR convergence 2024 further contribute to our understanding of this potential risk profile.
Read Article
JAKs and Other Drugs in PMR
This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with just glucocorticoids but we persist far too long with a glucocorticoid only strategy in others who clearly need an alternative as glucocorticoid adverse events multiply.
Read Article
RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh
JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P
Janet Pope Janetbirdope ( View Tweet)
